Comorbidities of psoriatic arthritis - Metabolic syndrome and prevention

A report from the GRAPPA 2010 annual meeting

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Psoriatic arthritis (PsA) is associated with serious comorbidities such as increased cardiovascular risk, hypertension, depression, and reduced quality of life. Patients with psoriasis have been observed to have an increased incidence of metabolic syndrome compared with the general population; recently, this has also been observed in patients with PsA. This review focuses on the comorbidities associated with PsA, with an emphasis on risks of coronary artery disease and metabolic syndrome. We also discuss the development of a comprehensive approach for the management of comorbidities of PsA. The review summarizes a presentation at the 2010 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)437-440
Number of pages4
JournalJournal of Rheumatology
Volume39
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Psoriatic Arthritis
Psoriasis
Comorbidity
Research
Group Processes
Rheumatology
Coronary Artery Disease
Quality of Life
Depression
Hypertension
Incidence
Population

Keywords

  • Comorbidities
  • Metabolic syndrome
  • Prevention
  • Psoriatic arthritis
  • Total care

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

@article{9878687be94545e7ac11285da03d940f,
title = "Comorbidities of psoriatic arthritis - Metabolic syndrome and prevention: A report from the GRAPPA 2010 annual meeting",
abstract = "Psoriatic arthritis (PsA) is associated with serious comorbidities such as increased cardiovascular risk, hypertension, depression, and reduced quality of life. Patients with psoriasis have been observed to have an increased incidence of metabolic syndrome compared with the general population; recently, this has also been observed in patients with PsA. This review focuses on the comorbidities associated with PsA, with an emphasis on risks of coronary artery disease and metabolic syndrome. We also discuss the development of a comprehensive approach for the management of comorbidities of PsA. The review summarizes a presentation at the 2010 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). The Journal of Rheumatology",
keywords = "Comorbidities, Metabolic syndrome, Prevention, Psoriatic arthritis, Total care",
author = "Raychaudhuri, {Siba P}",
year = "2012",
month = "2",
doi = "10.3899/jrheum.111244",
language = "English (US)",
volume = "39",
pages = "437--440",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Comorbidities of psoriatic arthritis - Metabolic syndrome and prevention

T2 - A report from the GRAPPA 2010 annual meeting

AU - Raychaudhuri, Siba P

PY - 2012/2

Y1 - 2012/2

N2 - Psoriatic arthritis (PsA) is associated with serious comorbidities such as increased cardiovascular risk, hypertension, depression, and reduced quality of life. Patients with psoriasis have been observed to have an increased incidence of metabolic syndrome compared with the general population; recently, this has also been observed in patients with PsA. This review focuses on the comorbidities associated with PsA, with an emphasis on risks of coronary artery disease and metabolic syndrome. We also discuss the development of a comprehensive approach for the management of comorbidities of PsA. The review summarizes a presentation at the 2010 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). The Journal of Rheumatology

AB - Psoriatic arthritis (PsA) is associated with serious comorbidities such as increased cardiovascular risk, hypertension, depression, and reduced quality of life. Patients with psoriasis have been observed to have an increased incidence of metabolic syndrome compared with the general population; recently, this has also been observed in patients with PsA. This review focuses on the comorbidities associated with PsA, with an emphasis on risks of coronary artery disease and metabolic syndrome. We also discuss the development of a comprehensive approach for the management of comorbidities of PsA. The review summarizes a presentation at the 2010 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). The Journal of Rheumatology

KW - Comorbidities

KW - Metabolic syndrome

KW - Prevention

KW - Psoriatic arthritis

KW - Total care

UR - http://www.scopus.com/inward/record.url?scp=84856529650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856529650&partnerID=8YFLogxK

U2 - 10.3899/jrheum.111244

DO - 10.3899/jrheum.111244

M3 - Article

VL - 39

SP - 437

EP - 440

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -